- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 473/26 - Heterocyclic compounds containing purine ring systems with an oxygen, sulfur, or nitrogen atom directly attached in position 2 or 6, but not in both
Patent holdings for IPC class C07D 473/26
Total number of patents in this class: 27
10-year publication summary
|
3
|
0
|
1
|
4
|
2
|
5
|
0
|
2
|
1
|
0
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| AstraZeneca AB | 2820 |
3 |
| Board of Regents, The University of Texas System | 6127 |
3 |
| University of Georgia Research Foundation, Inc. | 1077 |
3 |
| ArQule, Inc. | 132 |
2 |
| The Brigham and Women's Hospital, Inc. | 2290 |
2 |
| The Broad Institute, Inc. | 1979 |
2 |
| Novartis AG | 10224 |
1 |
| AstraZeneca UK Limited | 527 |
1 |
| President and Fellows of Harvard College | 6096 |
1 |
| Asana Biosciences, LLC | 42 |
1 |
| Incyte Holdings Corporation | 625 |
1 |
| Kissei Pharmaceutical Co., Ltd. | 177 |
1 |
| Medical Research Council | 127 |
1 |
| Signal Pharmaceuticals, LLC | 176 |
1 |
| Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | 1354 |
1 |
| Aligos Therapeutics, Inc. | 164 |
1 |
| Micar Innovation Ltd. | 3 |
1 |
| Yissum Research Development Company of the Hebrew University of Imersualem Ltd. | 1 |
1 |
| Other owners | 0 |